index,Regulator Name,Regulator Type,Regulator Subtype,Regulator HGNC Symbol,Regulator Database,Regulator ID,Regulator Compartment,Regulator Compartment ID,Regulated Name,Regulated Type,Regulated Subtype,Regulated HGNC Symbol,Regulated Database,Regulated ID,Regulated Compartment,Regulated Compartment ID,Sign,Connection Type,Mechanism,Site,Cell Line,Cell Type,Tissue Type,Organism,Unnamed: 0,Score,Source,Statements,Paper IDs,Evidence Score,Match Score,Kind Score,Epistemic Value,Total Score
146,ras,protein,,ras,uniprot,q92062,cytoplasm,go:0005739,kras,protein,,kras,uniprot,q92063,cytoplasm,go:0005739,positive,d,phosphorylation,,,b-cell,,human,['55'],nan,nan,"ras proto-oncogenes encode small gtpase proteins, that is, kras, nras and hras, that are involved in homeostatic mechanisms of proliferation, differentiation and apoptosis of normal cells [29]. whereas kras and nras are frequently mutated and activated in aml, hras mutations are rare, and hras wild-type expression is the lowest with respect to the other ras isoforms in the hematopoietic system [29]. aberrant activation of ras signal transduction is often found in human neoplasia [30â€“43]. in hematopoietic malignancies, including aml, activating oncogenic ras mutations contribute to malignant phenotypes by phosphorylating and activating downstream effectors such as the mitogen-activated protein kinase kinase (mapkk, also known as mek), mitogen-activated protein kinase (mapk), and the pi3k-akt downstream effectors, thereby promoting aberrant cell proliferation and survival [29]. however, to date, an effective therapeutic approach targeting ras directly remains to be developed.",pmc5312311,1,10,18,1,28
149,ras,protein,,ras,uniprot,q92677,plasma membrane,go:0005886,kras,protein,,kras,uniprot,q92677,plasma membrane,go:0005886,positive,d,mutation,,,,,human,['99'],nan,nan,"through an integrated analysis of literature data and internal datasets incorporating both cell line models and human tumors, we identified a ras pathway signature consisting of 147 genes that is coherently expressed across multiple datasets. the ras pathway signature has a high sensitivity for detecting kras mutant cell lines and human tumors, but also identifies samples that have apparent ras pathway activation in the absence of a kras mutation. we show that baseline levels of the ras pathway signature predict resistance to akt inhibition and sensitivity to mek inhibition in cell line panels independent of kras mutation status, that the signature is downregulated by mek inhibition, and that the signature is a better predictor of ras pathway dependence compared to kras mutation status in lung cancer cell lines. in human tumors, the ras signature is coherent across multiple tumor types, is elevated in clinical subtypes not known to harbor kras mutations (i.e. er negative breast cancer), and predicts resistance to cetuximab in metastatic colorectal cancer. these data demonstrate that the ras signature significantly expands the population of human tumors exhibiting ras pathway deregulation, and has potential clinical utility in identifying lung and breast tumors where ras pathway dependence should be considered when choosing appropriate targeted therapies.",pmc2911390,1,10,18,1,28
